Cardiac Dimensions

Cardiac Dimensions develops the Carillon Mitral Contour System, a minimally invasive implant for treating functional mitral regurgitation associated with heart failure. The device has CE Mark approval and commercial availability in Europe and the Middle East. In the U.S., it remains investigational and under evaluation in the pivotal EMPOWER clinical trial. Published research demonstrates improvements in quality-of-life metrics for patients treated with Carillon therapy, including symptom relief and potential survival benefit. The company recently raised $53 million to complete its U.S. pivotal study and expand commercialization efforts globally.